Non-responders to Antiplatelet Treatment in Acute Ischaemic Stroke)
Launched by ZEALAND UNIVERSITY HOSPITAL · Nov 17, 2015
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
Determination of frequency of Clopidigrel- and Acetacylicacid-non-responders (HOTPR) in acute ischemic stroke patients using the VerifyNow system.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Suspected acute ischemic stroke and loading dose of Clopidogrel or Acetacylicacid
- Exclusion Criteria:
- • Previous treatment with platelet inhibitor
- • NOAC or Vitamin K-antagonist treatment
- • Final diagnosis other than Ischemoc stroke or Transitoric ischemic attack
About Zealand University Hospital
Zealand University Hospital is a leading academic medical center located in Denmark, dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital leverages its extensive expertise in various medical fields to improve patient outcomes and enhance treatment methodologies. With a commitment to rigorous scientific standards and ethical practices, Zealand University Hospital collaborates with multidisciplinary teams to explore new therapies and interventions, contributing significantly to the global body of medical knowledge. Through its state-of-the-art facilities and focus on patient-centered care, the hospital plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roskilde, , Denmark
Patients applied
Trial Officials
Charlotte Rath, MD
Principal Investigator
Zealand University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials